Navigation Links
Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
Date:4/9/2008

to boost immune responses. Favrille's unique and proprietary manufacturing process, which includes an insect cell (baculovirus) expression system, allows for the manufacture of Specifid for delivery to patients in as few as eight weeks. Data presented at the American Society of Hematology Annual Meeting in December 2007 showed that Id-KLH produced via insect cells results in a more immunogenic response compared to Id-KLH produced in a traditional mammalian cell manufacturing process. Also, unlike other Id-KLH active immunotherapies in development, Specifid is intended for use as a chronic therapy and is administered until the patient's disease progresses.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid (mitumprotimut-T, formerly FavId), is a patient-specific, active immunotherapy based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a Phase 3 registration trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

The preliminary, blinded clinical data reported from time to time prior to the release of the final results of Favrille's Phase 3 registration trial have not been audited and have been taken from databases that have not been reconciled against medical records kept at the clinical sites or that may not include the most current information on patient disease progressions. The data released may not be indicative of the final results of Favrille's Phase 3 registration trial Failure can oc
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
2. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
6. Medarex Announces Ipilimumab Program Continues to Move Forward
7. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
8. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
9. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
10. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Utah , Aug. 29, 2014  BC Technical, ... has acquired Polaris Medical Imaging, a leader in sales, ... This strategic acquisition allows BC Technical to continue to ... specifically within MR and CT modalities. ... service," said Mark Alvarez , president and CEO ...
(Date:8/29/2014)... -- According to a new market ... (SFE, Cold Pressed, Organic Solvent, & Others), and by ... & Others) - Global Trends & Forecast to ... Amaranth Seed Oil Market with an analysis and ... value. The Amaranth Seed Oil Market size in ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... March 30, 2011 MonoSol Rx, the developers ... specializing in proprietary pharmaceutical film products, today announced ... meeting with the U.S. Food and Drug Administration ... Soluble Film (OSF) under a 505(b)(2) pathway.  The ...
... 30, 2011 Cara Therapeutics, Inc. today announced the ... position of Chief Medical Officer.  In this role, Dr. ... lead drug candidate, CR845, a novel, peripherally-restricted kappa opioid ... treatment of post-operative pain. "We are delighted ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer 2Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer 3
(Date:8/30/2014)... 30, 2014 According to Bloomberg ... that requires Takeda Pharmaceutical Co. and Eli Lilly & ... claims that the drugmakers concealed information about a risk ... The case, Allen v. Takeda Pharmaceuticals North America Inc. ... District of Louisiana (Lafayette).* , According to Bloomberg, Takeda ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... August 30, 2014 Daily Gossip magazine ... keeps anxiety and panic attacks under control with a ... program review describes this new method as an ... panic attacks and overcome general anxiety related disorders. ... is the fact that it can be accessed by ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 RB SEO ... cost SEO service for small businesses. , RBSEO Services ... cannot afford costly search engine optimization service. So, the ... small businesses into account. , On being asked ... have introduced this low cost SEO service because many ...
(Date:8/30/2014)... a common problem millions of American cope with every day. While ... for some, it can have a crippling impact on social activity ... mood swings and depression. , Those struggling with acne are ... some cases, that can make the problem even worse. Instead of ... quest for clearer skin can now view acne treatment reviews ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... , BOSTON, Oct. 16 Dr. Sanjay Gupta, CNN chief ... Hill Community College "Compelling Conversations" speaker series. ... in the A300 auditorium. , A leader in ... to the CNN television shows "American Morning" and "House Call ...
... The European Society of Cardiology wishes to comment on ... authorise the sale of cigarettes on the internet, to ... denies that this is the intention, the news is ... last year,s smoking ban. ESC spokesperson Professeur Ph.Gabriel ...
... WASHINGTON, October 16, 2009 MedImmune announced today it ... Pediatrics (AAP) 2009 National Conference & Exhibition that add ... burden of respiratory syncytial virus (RSV) on children, as ... influenza and RSV becoming more widespread this time of ...
... Area School District in Bradford County today became the ... influenza vaccine to its student population, the Department of ... all parents that immunizations play a significant role in ... affecting school-aged children, with almost two-thirds of all cases ...
... double the national average, researchers say , FRIDAY, Oct. 16 ... Milwaukee,s poorest neighborhoods smoke -- more than twice the national ... even while most of the households reported earning less than ... that a large number of these low-income smokers hold beliefs ...
... Oct. 16 More Vermont physicians will be using ... patient care, under a $1 million federal grant secured ... by Leahy and Vermont Information Technology Leaders, Inc. (VITL), ... adopt health information technology. , In June, Vermont was ...
Cached Medicine News:Health News:CNN Medical Correspondent Sanjay Gupta to Speak at Bunker Hill Community College 2Health News:ESC press statement : Cigarettes on sale on the internet 2Health News:ESC press statement : Cigarettes on sale on the internet 3Health News:MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 2Health News:MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 3Health News:Pennsylvania Department of Health Announces First School to Begin Administering H1N1 Vaccine to Students 2Health News:Smoking Keeps Its Grip on Urban Poor 2Health News:Smoking Keeps Its Grip on Urban Poor 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 4Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 5
4.625 inches, curved blade 4 mm....
Walton foreign body gouge 4 1/2 inches, round end....
... made from MMA/VP material and has a high ... supplied with the base curve and total diameter ... available in a power range of -30.00DS to ... protective and therapeutic applications including the controlled on-eye ...
... premium high water content ... permeability. Standard one fit ... the following therapeutic conditions: ... bullous keratopathy, recurrent ulcers, ...
Medicine Products: